利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.036 秒)

    Patient classification
    5.
    发明授权
    Patient classification 有权
    患者分类

    公开(公告)号：US07908089B2

    公开(公告)日：2011-03-15

    申请号：US10856564

    申请日：2004-05-27

    申请人： Ellen L. Berg ,  Eugene C. Butcher ,  Jennifer Melrose

    发明人： Ellen L. Berg ,  Eugene C. Butcher ,  Jennifer Melrose

    IPC分类号： G06F19/00 ,  G06F17/30 ,  C12Q1/00

    CPC分类号： G01N33/5091 ,  G01N33/5005 ,  G01N33/5008 ,  G01N33/5011 ,  G01N33/5023 ,  G01N33/5041 ,  G01N33/6863 ,  G01N33/6866 ,  G01N33/6869 ,  G01N33/6872 ,  G06F19/12 ,  G06F19/24 ,  G06F19/26

    摘要： Clinical patient tissue samples are classified according to the physiological status of cells present in the sample. In some embodiments of the invention, such cells are classified according to their ability to respond to therapeutic agents and treatments. In other embodiments, the cells or tissue samples are classified according to their status with respect to the activity of pathways of interest. The information thus derived is useful in prognosis and diagnosis, and can further be used develop surrogate markers for disease states, and to investigate the effect of genetic polymorphisms in the responsiveness and state of cells involved in disease.

    摘要翻译： 临床患者组织样本根据样品中存在的细胞的生理状态进行分类。 在本发明的一些实施方案中，这样的细胞根据其对治疗剂和治疗的反应能力进行分类。 在其它实施方案中，细胞或组织样品根据其关于感兴趣途径的活性的状态来分类。 因此得出的信息对预后和诊断有用，并且可以进一步用于开发疾病状态的替代标志物，并且研究遗传多态性对涉及疾病的细胞的反应性和状态的影响。

    Patient classification
    6.
    发明授权
    Patient classification 有权
    患者分类

    公开(公告)号：US06763307B2

    公开(公告)日：2004-07-13

    申请号：US09952744

    申请日：2001-09-13

    申请人： Ellen L. Berg ,  Eugene C. Butcher ,  Jennifer Melrose

    发明人： Ellen L. Berg ,  Eugene C. Butcher ,  Jennifer Melrose

    IPC分类号： G06F1900

    CPC分类号： G01N33/5091 ,  G01N33/5005 ,  G01N33/5008 ,  G01N33/5011 ,  G01N33/5023 ,  G01N33/5041 ,  G01N33/6863 ,  G01N33/6866 ,  G01N33/6869 ,  G01N33/6872 ,  G06F19/12 ,  G06F19/24 ,  G06F19/26

    摘要： Clinical patient tissue samples are classified according to the physiological status of cells present in the sample. In some embodiments of the invention, such cells are classified according to their ability to respond to therapeutic agents and treatments. In other embodiments, the cells or tissue samples are classified according to their status with respect to the activity of pathways of interest. The information thus derived is useful in prognosis and diagnosis, and can further be used develop surrogate markers for disease states, and to investigate the effect of genetic polymorphisms in the responsiveness and state of cells involved in disease.

    摘要翻译： 临床患者组织样本根据样品中存在的细胞的生理状态进行分类。 在本发明的一些实施方案中，这样的细胞根据其对治疗剂和治疗的反应能力进行分类。 在其它实施方案中，细胞或组织样品根据其关于感兴趣途径的活性的状态来分类。 因此得出的信息对预后和诊断有用，并且可以进一步用于发展疾病状态的替代标志物，并且研究遗传多态性对涉及疾病的细胞的反应性和状态的影响。

    Leukocyte homing modulation
    7.
    发明授权
    Leukocyte homing modulation 失效
    白细胞归巢调制

    公开(公告)号：US06387884B1

    公开(公告)日：2002-05-14

    申请号：US08336417

    申请日：1994-11-09

    申请人： John L. Magnani ,  Eugene C. Butcher ,  Ellen L. Berg

    发明人： John L. Magnani ,  Eugene C. Butcher ,  Ellen L. Berg

    IPC分类号： A61K3170

    CPC分类号： C07H13/04 ,  A61K38/47 ,  A61K47/56 ,  C07K14/705 ,  C07K14/70564 ,  C07K16/30

    摘要： Novel methods and compositions are provided for modulating homing of leukocytes, particularly lymphocytes, where the compounds are cross-reactive with Neu5Ac2-3Gal&bgr;1−X[Fuc&agr;1−y]GlcNAc, where one of x and y is three and the other is four. These compounds may be administered to a host associated with inflammation, to avoid the deleterious effects of leukocyte infiltration.

    摘要翻译： 提供新的方法和组合物用于调节白细胞，特别是淋巴细胞的归巢，其中化合物与Neu5Ac2-3Galbeta1-X [Fucalpha1-y] GlcNAc交叉反应，其中x和y之一是三个，另一个是四个。 这些化合物可以施用于与炎症相关的宿主，以避免白细胞浸润的有害作用。

    Methods and compositions for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
    9.
    发明授权
    Methods and compositions for the inhibition of cancer metastasis mediated by endothelial adhesion molecules 失效
    用于抑制内皮粘附分子介导的癌转移的方法和组合物

    公开(公告)号：US06465434B1

    公开(公告)日：2002-10-15

    申请号：US09447532

    申请日：1999-11-23

    申请人： John L. Magnani ,  Eugene C. Butcher ,  Ellen L. Berg

    发明人： John L. Magnani ,  Eugene C. Butcher ,  Ellen L. Berg

    IPC分类号： A01N4304

    CPC分类号： C07H13/04 ,  A61K38/47 ,  A61K47/56 ,  C07K14/70564 ,  C07K16/30

    摘要： Methods and compositions are disclosed for the inhibition of cancer metastases mediated by endothelial adhesion molecules. The present invention discloses that sialyl Lea and di-sialyl Lea, which are expressed at the surface of cancer cells, function as a binding partner for LEC-CAMs, such as ELAM-1, which are expressed at the surface of endothelial cells. The present invention also discloses that LEC-CAMs, such as ELAM-1, involved in cancer metastasis share a carbohydrate domain common to both sialyl Lea and sialyl Lex. Antibodies, saccharides, glycoconjugates, enzyme inhibitors and other compounds may be used in the methods of the present invention to inhibit the binding of malignant cells to endothelial cells for a variety of purposes in vivo and in vitro.

    摘要翻译： 公开了用于抑制由内皮粘附分子介导的癌转移的方法和组合物。 本发明公开了在癌细胞表面表达的唾液酸Lea和二唾液酸Lea作为LEC-CAM的结合配偶体，如在内皮细胞表面表达的ELAM-1。 本发明还公开了涉及癌症转移的LEC-CAM，如ELAM-1，共享唾液酸Lea和唾液酸Lex共同的碳水化合物结构域。 抗体，糖，糖缀合物，酶抑制剂和其它化合物可用于本发明的方法中，以体内和体外抑制恶性细胞与内皮细胞的结合，用于多种目的。

    Methods and compositions for endothelial binding
    10.
    发明授权
    Methods and compositions for endothelial binding 失效
    用于内皮结合的方法和组合物

    公开(公告)号：US06391857B1

    公开(公告)日：2002-05-21

    申请号：US08336466

    申请日：1994-11-09

    申请人： John L. Magnani ,  Eugene C. Butcher ,  Ellen L. Berg

    发明人： John L. Magnani ,  Eugene C. Butcher ,  Ellen L. Berg

    IPC分类号： A61K3170

    CPC分类号： C07H13/04 ,  A61K38/47 ,  A61K47/56 ,  C07K14/705 ,  C07K14/70564 ,  C07K16/30 ,  Y10S530/807

    摘要： Novel methods and compositions are provided for modulating homing of leukocytes, particularly lympho-cytes, where the compounds are cross-reactive with Neu5Ac2-3Gal&bgr;1-X[Fuc&agr;1-y]GlcNAc, where one of x and y is three and the other is four. These compounds may be administered to a host associated with inflammation, to avoid the deleterious effects of leukocyte infiltration and for directing molecules to such sites.

    摘要翻译： 提供新的方法和组合物用于调节白细胞，特别是淋巴细胞的归巢，其中化合物与Neu5Ac2-3Galbeta1-X [Fucalpha1-y] GlcNAc交叉反应，其中x和y之一是三个，另一个是四个 。 这些化合物可以施用于与炎症相关的宿主，以避免白细胞浸润的有害作用并将分子引导到这些位点。